

# Claire E Higham

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2834520/publications.pdf>

Version: 2024-02-01

53  
papers

2,537  
citations

218381

26  
h-index

205818

48  
g-index

53  
all docs

53  
docs citations

53  
times ranked

3446  
citing authors

#	ARTICLE	IF	CITATIONS
1	Value of Early Post-Operative Growth Hormone Testing in Predicting Long-Term Remission and Residual Disease after Transsphenoidal Surgery for Acromegaly. <i>Neuroendocrinology</i> , 2022, 112, 345-357.	1.2	5
2	Regulation of bone mass in endocrine diseases including diabetes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2022, 36, 101614.	2.2	3
3	Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. <i>European Journal of Endocrinology</i> , 2022, 186, P35-P52.	1.9	42
4	RadBone: bone toxicity following pelvic radiotherapy – a prospective randomised controlled feasibility study evaluating a musculoskeletal health package in women with gynaecological cancers undergoing pelvic radiotherapy. <i>BMJ Open</i> , 2022, 12, e056600.	0.8	1
5	Real-World Estimates of Adrenal Insufficiency-Related Adverse Events in Children With Congenital Adrenal Hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e192-e203.	1.8	20
6	Clinical Experience of the Efficacy and Safety of Low-dose Tolvaptan Therapy in a UK Tertiary Oncology Setting. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4766-e4775.	1.8	7
7	Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors – a review of research and clinical practice. <i>Pituitary</i> , 2021, 24, 810-827.	1.6	17
8	Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 622-637.	5.5	29
9	Plasma Renin Measurements are Unrelated to Mineralocorticoid Replacement Dose in Patients With Primary Adrenal Insufficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 314-326.	1.8	30
10	Outcomes of Patients with Nelson's Syndrome after Primary Treatment: A Multicenter Study from 13 UK Pituitary Centers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1527-1537.	1.8	26
11	Neurokinin 3 Receptor Antagonists Do Not Increase FSH or Estradiol Secretion in Menopausal Women. <i>Journal of the Endocrine Society</i> , 2020, 4, bvz009.	0.1	5
12	Primary epithelial-myoeptithelial carcinoma of the pituitary gland. <i>Neuropathology</i> , 2020, 40, 261-267.	0.7	4
13	RE: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer. <i>European Journal of Cancer</i> , 2020, 136, 204-205.	1.3	2
14	Adjuvant immunotherapy: the sting in the tail. <i>European Journal of Cancer</i> , 2020, 132, 207-210.	1.3	20
15	Oestradiol measurement during fulvestrant treatment for breast cancer. <i>British Journal of Cancer</i> , 2019, 120, 404-406.	2.9	18
16	Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study. <i>Thyroid</i> , 2019, 29, 1003-1011.	2.4	72
17	Long-Term Endocrine and Metabolic Consequences of Cancer Treatment: A Systematic Review. <i>Endocrine Reviews</i> , 2019, 40, 711-767.	8.9	91
18	Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial. <i>European Journal of Endocrinology</i> , 2018, 178, 491-499.	1.9	47

#	ARTICLE	IF	CITATIONS
19	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. <i>European Journal of Endocrinology</i> , 2018, 178, 265-276.	1.9	196
20	Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis associated with pelvic radiotherapy in adults. <i>The Cochrane Library</i> , 2018, 4, CD010604.	1.5	13
21	Effects of random glucose (Glc) levels on outcomes of patients (pts) with pancreatic ductal adenocarcinoma (PDAC). <i>Annals of Oncology</i> , 2018, 29, viii256.	0.6	1
22	Emergency management of immune-related hypophysitis: Collaboration between specialists is essential to achieve optimal outcomes. <i>Cancer</i> , 2018, 124, 4731-4731.	2.0	4
23	SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy. <i>Endocrine Connections</i> , 2018, 7, G1-G7.	0.8	97
24	Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (<scp>JBDS</scp>) for Inpatient Care group. <i>Diabetic Medicine</i> , 2018, 35, 1011-1017.	1.2	87
25	Joint British Diabetes Societies for Inpatient Care: clinical guidelines and improving inpatient diabetes care. <i>Diabetic Medicine</i> , 2018, 35, 988-991.	1.2	16
26	Fanconi anemia with sun-sensitivity caused by a Xeroderma pigmentosum-associated missense mutation in XPF. <i>BMC Medical Genetics</i> , 2018, 19, 7.	2.1	9
27	Pituitary hormone replacement. <i>Medicine</i> , 2017, 45, 470-474.	0.2	0
28	Proopiomelanocortin interference in the measurement of adrenocorticotrophic hormone: a United Kingdom National External Quality Assessment Service study. <i>Clinical Endocrinology</i> , 2016, 85, 569-574.	1.2	12
29	Hypopituitarism. <i>Lancet, The</i> , 2016, 388, 2403-2415.	6.3	195
30	GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. <i>European Journal of Endocrinology</i> , 2016, 174, P1-P9.	1.9	184
31	Hyponatraemia secondary to nivolumab-induced primary adrenal failure. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, .	0.2	60
32	Heterogeneous Genetic Background of the Association of Pheochromocytoma/Paraganglioma and Pituitary Adenoma: Results From a Large Patient Cohort. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E531-E541.	1.8	145
33	Bone Health and Pelvic Radiotherapy. <i>Clinical Oncology</i> , 2015, 27, 668-678.	0.6	49
34	60 YEARS OF NEUROENDOCRINOLOGY: The hypothalamo-GH axis: the past 60 years. <i>Journal of Endocrinology</i> , 2015, 226, T123-T140.	1.2	58
35	Pituitary hormone replacement. <i>Medicine</i> , 2013, 41, 504-507.	0.2	0
36	Effective Combination Treatment with Cabergoline and Low-Dose Pegvisomant in Active Acromegaly: A Prospective Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1187-1193.	1.8	90

#	ARTICLE	IF	CITATIONS
37	Effective Combination Treatment with Cabergoline and Low-Dose Pegvisomant in Active Acromegaly. Obstetrical and Gynecological Survey, 2012, 67, 475-476.	0.2	1
38	Acromegaly surgery in Manchester revisited – The impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission. Clinical Endocrinology, 2012, 76, 399-406.	1.2	57
39	GHR Antagonist: Efficacy and Safety. , 2011, , 339-357.		0
40	Licorice – or more?. Experimental and Clinical Endocrinology and Diabetes, 2010, 118, 250-253.	0.6	7
41	Successful use of weekly pegvisomant administration in patients with acromegaly. European Journal of Endocrinology, 2009, 161, 21-25.	1.9	38
42	Pegvisomant Improves Insulin Sensitivity and Reduces Overnight Free Fatty Acid Concentrations in Patients with Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2459-2463.	1.8	66
43	Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample. European Journal of Endocrinology, 2009, 161, 705-713.	1.9	77
44	Pituitary hormone replacement. Medicine, 2009, 37, 399-402.	0.2	0
45	Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clinical Endocrinology, 2009, 71, 86-91.	1.2	62
46	Growth hormone excess and the development of growth hormone receptor antagonists. Experimental Physiology, 2008, 93, 1157-1169.	0.9	30
47	IGF-I measurements in the monitoring of GH therapy. Pituitary, 2007, 10, 159-163.	1.6	16
48	Identification of a novel human islet amyloid polypeptide $\beta$ -sheet domain and factors influencing fibrillogenesis. Journal of Molecular Biology, 2001, 308, 515-525.	2.0	226
49	Processing of synthetic pro-islet amyloid polypeptide (proIAPP) – amylin™ by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro. FEBS Journal, 2000, 267, 4998-5004.	0.2	49
50	The antimalarial agent mefloquine inhibits ATP-sensitive K-channels. British Journal of Pharmacology, 2000, 131, 756-760.	2.7	75
51	Preparation of synthetic human islet amyloid polypeptide (IAPP) in a stable conformation to enable study of conversion to amyloid-like fibrils. FEBS Letters, 2000, 470, 55-60.	1.3	114
52	Formation of amyloid fibrils by peptides derived from the bacterial cold shock protein CspB. Protein Science, 1999, 8, 1350-1357.	3.1	63
53	Pharmacological interventions for the prevention of insufficiency fractures and avascular necrosis associated with pelvic radiotherapy in adults. The Cochrane Library, 0, , .	1.5	1